Aiforia Technologies Oyj, together with its subsidiary Aiforia Inc., equips pathologists and scientists in preclinical, clinical, and academic labs with deep learning artificial intelligence (AI) software in Finland, the rest of Europe, North America, and internationally. It offers tools for AI-supported diagnostics and visualization of patient samples, as well as automated screening and reporting tools for the treatment of various cancers, such as breast, lung, and prostate cancer; CE-IVD marked Aiforia clinical suite viewer for the clinical pathology workflow; and Aiforia Create, an agile solution to develop an AI model for image analysis application. The company’s products are used for the treatment of Parkinson’s disease, organ transplantation, and liver and inflammatory bowel diseases. It serves academic institutes and pharmaceutical companies through direct and partner sales. Aiforia Technologies Oyj was incorporated in 2013 and is headquartered in Helsinki, Finland.
Finnish Market Performance
7D7 Days: 1.0%
3M3 Months: 9.7%
1Y1 Year: 8.9%
YTDYear to Date: 11.6%
The Energy sector gained 12% while the market remained flat over the last week. As for the longer term, the market has risen 8.9% in the past 12 months. As for the next few years, earnings are expected to grow by 16% per annum. Market details ›
Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...